“GENDER-BASED ANALYSIS OF ADVERSE EFFECTS OF DAPAGLIFLOZIN AND EMPAGLIFLOZIN IN CHRONIC KIDNEY DISEASE ASSOCIATED WITH TYPE 2 DIABETES: A COMPARATIVE ”. 2025. Global Science Review 2 (1): 418-22. https://global-science-review.com/ojs/index.php/gsr/article/view/238.